Tag: zeroblunt
Development of a novel reporter gene assay to evaluate antibody-dependent cellular phagocytosis for anti-CD20 therapeutic antibodies
Greater than 100 monoclonal antibodies (mAbs) have been accepted by FDA. The mechanism of motion (MoA) includes in neutralization of a selected goal by way of the Fab area and Fc effector features by Fc area, whereas the latter embody complement-dependent cytotoxicity (CDC), antibody-dependent cell-mediated cytotoxicity (ADCC) and antibody-dependent mobile phagocytosis (ADCP). ADCP has been acknowledged one of the…
Read More